{"preliminary_commentary":{"by_channel":{"x_thread":37,"youtube":23,"podcast":21,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02627963\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["tivozanib"]],"indication":"relapsed/refractory advanced renal cell carcinoma","name":"TIVO-3","nct_id":"NCT02627963","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tivo-3-nct02627963. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants randomized to this arm will receive the study drug, tivozanib hydrochloride.","label":"Tivozanib hydrochloride","type":"EXPERIMENTAL"},{"description":"Participants randomized to this arm will receive the comparator drug, sorafenib.","label":"Sorafenib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2021-06-21","type":"ACTUAL"},"conditions":["Carcinoma, Renal Cell"],"enrollment":{"count":350,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Tivozanib hydrochloride","otherNames":[],"type":"DRUG"},{"name":"Sorafenib","otherNames":[],"type":"DRUG"}],"last_update":"2023-07-18","lead_sponsor":"AVEO Pharmaceuticals, Inc.","official_title":"A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2018-10-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS)","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first. Disease progression was assessed every 8 weeks (up to approximately 5 years)"}],"references":[{"citation":"Beckermann KE, Asnis-Alibozek AG, Atkins MB, Escudier B, Hutson TE, Kasturi V, McDermott DF, Pal SK, Porta C, Rini BI, Verzoni E. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. Oncologist. 2024 Mar 4;29(3):254-262. doi: 10.1093/oncolo/oyad348.","pmid":"38262444","type":"DERIVED"},{"citation":"Meza L, McDermott DF, Escudier B, Hutson TE, Porta C, Verzoni E, Atkins MB, Kasturi V, Pal SK, Rini B. Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3. Oncologist. 2023 Mar 17;28(3):e167-e170. doi: 10.1093/oncolo/oyac255.","pmid":"36576430","type":"DERIVED"},{"citation":"Szarek M, Needle MN, Rini BI, Pal SK, McDermott DF, Atkins MB, Hutson TE, Escudier BJ. Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. Clin Genitourin Cancer. 2021 Oct;19(5):468.e1-468.e5. doi: 10.1016/j.clgc.2021.03.018. Epub 2021 Apr 3.","pmid":"33980467","type":"DERIVED"},{"citation":"Rini BI, Pal SK, Escudier BJ, Atkins MB, Hutson TE, Porta C, Verzoni E, Needle MN, McDermott DF. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2020 Jan;21(1):95-104. doi: 10.1016/S1470-2045(19)30735-1. Epub 2019 Dec 3.","pmid":"31810797","type":"DERIVED"}],"start_date":{"date":"2016-05-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)","url":"https://clinicaltrials.gov/study/NCT02627963"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tivo-3-nct02627963"}